MedPath

Amlodipine

Generic Name
Amlodipine
Brand Names
Amlobenz, Azor, Caduet, Dafiro, Exforge, Exforge Hct, Katerzia, Lotrel, Norliqva, Norvasc, Prestalia, Tribenzor, Twynsta, Viacoram
Drug Type
Small Molecule
Chemical Formula
C20H25ClN2O5
CAS Number
88150-42-9
Unique Ingredient Identifier
1J444QC288

Overview

Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers . Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .

Background

Amlodipine, initially approved by the FDA in 1987, is a popular antihypertensive drug belonging to the group of drugs called dihydropyridine calcium channel blockers. Due to their selectivity for the peripheral blood vessels, dihydropyridine calcium channel blockers are associated with a lower incidence of myocardial depression and cardiac conduction abnormalities than other calcium channel blockers . Amlodipine is commonly used in the treatment of high blood pressure and angina. Amlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure . The option for single daily dosing of amlodipine is an attractive feature of this drug .

Indication

Amlodipine may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of the following conditions : • Hypertension • Coronary artery disease • Chronic stable angina • Vasospastic angina (Prinzmetal’s or Variant angina) • Angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%

Associated Conditions

  • Cardiovascular Events
  • Chronic Stable Angina Pectoris
  • Coronary Artery Disease (CAD)
  • Homozygous Familial Hypercholesterolaemia (HoFH)
  • Hypertension
  • Hypertension, Essential Hypertension
  • Mixed Dyslipidemias
  • Primary Hypercholesterolemia
  • Vasospastic Angina

FDA Approved Products

Amlodipine Besylate
Manufacturer:PD-Rx Pharmaceuticals, Inc.
Route:ORAL
Strength:10 mg in 1 1
Approved: 2023/08/30
NDC:43063-041
Amlodipine and Valsartan
Manufacturer:Golden State Medical Supply, Inc.
Route:ORAL
Strength:5 mg in 1 1
Approved: 2023/11/01
NDC:51407-772
AMLODIPINE BESYLATE
Manufacturer:RPK Pharmaceuticals, Inc.
Route:ORAL
Strength:2.5 mg in 1 1
Approved: 2022/07/25
NDC:53002-1352
Amlodipine and Valsartan
Manufacturer:Alembic Pharmaceuticals Inc.
Route:ORAL
Strength:5 mg in 1 1
Approved: 2023/02/24
NDC:62332-205
Amlodipine and Benazepril Hydrochloride
Manufacturer:Aurobindo Pharma Limited
Route:ORAL
Strength:5 mg in 1 1
Approved: 2021/11/10
NDC:65862-585

Singapore Approved Products

CONCOR AMLO TABLET 5 mg/ 10 mg
Manufacturer:EGIS Pharmaceuticals PLC (Bökényföldi)
Form:TABLET
Strength:10mg
Online:Yes
Approved: 2016/06/21
Approval:SIN15034P
AMLODANE 10 TABLET 10MG
Manufacturer:Ind-Swift Limited.
Form:TABLET
Strength:10.00 mg
Online:Yes
Approved: 2022/02/11
Approval:SIN16427P
SWAMLO TABLETS 10MG
Manufacturer:Ind-Swift Limited
Form:TABLET
Strength:10MG
Online:Yes
Approved: 2012/07/04
Approval:SIN14187P
AMLODIPINE SANDOZ TABLETS 5MG
Manufacturer:Lek Pharmaceuticals d.d., Sandoz Grup Saglik Ürünleri Ilaclari San. Ve Tic. A.S. (GEBZE 2), Lek Pharmaceuticals d.d. (Lendava) (Primary and secondary packager), Lek S.A. (Strykow) (Primary and secondary packager)
Form:TABLET
Strength:5mg
Online:Yes
Approved: 2015/03/17
Approval:SIN14756P
LODIPIN TABLET 10MG
Manufacturer:IND-SWIFT LIMITED
Form:TABLET
Strength:10mg
Online:Yes
Approved: 2016/11/28
Approval:SIN15122P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath